<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention and treatment of glucocorticoid-induced osteoporosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention and treatment of glucocorticoid-induced osteoporosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention and treatment of glucocorticoid-induced osteoporosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold N Rosen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth G Saag, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glucocorticoid therapy is associated with an appreciable risk of bone loss, which is most pronounced in the first few months of use. In addition, glucocorticoids increase fracture risk, and fractures occur at higher bone mineral density (BMD) values than occur in postmenopausal osteoporosis. The increased risk of fracture has been reported with doses of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or its equivalent as low as 2.5 to 7.5 mg daily [<a href="#rid1">1</a>]. Thus, glucocorticoid-induced bone loss should be treated aggressively, particularly in those already at high risk for fracture (older age, prior fragility fracture). In other individuals, clinical risk factor and bone density assessment may help guide therapy. The prevention and treatment of glucocorticoid-induced bone loss will be reviewed here. The clinical features are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis"</a>.)</p><p>Many of the prevention and treatment strategies for glucocorticoid-induced bone loss are similar to those used to prevent and treat other causes of osteoporosis. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a> and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL MEASURES</span><span class="headingEndMark"> — </span>In an attempt to minimize bone loss, certain general principles should be followed in all patients receiving any dose of glucocorticoids for a duration of ≥3 months [<a href="#rid2">2-4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The dose and the duration of glucocorticoid therapy should be as low as possible because even what are thought to be replacement doses or chronic inhaled glucocorticoids can cause bone loss [<a href="#rid5">5</a>]. Alternative therapy should be used whenever possible. (See  <a class="medical medical_review" href="/z/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids", section on 'Osteoporosis and fracture risk in adults'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical therapy (such as inhaled glucocorticoids or glucocorticoid enemas for asthma or bowel disease, respectively) is preferred over enteral or parenteral glucocorticoids, whenever possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should do weightbearing exercises to prevent both bone loss and muscle atrophy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should avoid smoking and excess alcohol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should take measures to prevent falls.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CALCIUM AND VITAMIN D</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium and vitamin D</strong> – We agree with the American College of Rheumatology (ACR) Task Force osteoporosis guidelines, which suggest that all patients taking glucocorticoids (any dose with an anticipated duration of ≥3 months) maintain a total calcium intake of 1000 to 1200 mg/day and vitamin D intake of 600 to 800 international units/day through either diet and/or supplements [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p></p><p class="bulletIndent1">Glucocorticoids induce negative calcium balance by decreasing intestinal calcium absorption and increasing urinary calcium excretion [<a href="#rid6">6</a>]. Therefore, calcium supplementation may attenuate bone loss in patients taking glucocorticoids. In a meta-analysis of five randomized trials comparing calcium and vitamin D (<a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">cholecalciferol</a> or an active vitamin D metabolite) with calcium alone or placebo in patients taking glucocorticoids, there was significant improvement in lumbar spine and radial bone mineral density (BMD) in the calcium and vitamin D group (weighted mean difference between treatment and control groups 2.6 and 2.5 percent, respectively) [<a href="#rid7">7</a>]. The incidence of new, nontraumatic fractures was not significantly different (two trials, odds ratio [OR] 0.6, 95% CI 0.1-2.4).</p><p></p><p class="bulletIndent1">In one of the larger studies included in the meta-analysis, 96 patients with rheumatoid arthritis receiving low-dose glucocorticoid therapy (mean <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose 5.6 mg daily) were randomly assigned to <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a> (1000 mg of elemental calcium daily) plus <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">vitamin D3</a> (500 international units/day) or placebo [<a href="#rid8">8</a>]. The between-group difference in the annual rate of change in BMD was 2.65 percent (95% CI 0.73-4.57) and 2.08 percent (95% CI 0.43-3.73) for the spine and trochanter, respectively, favoring calcium and vitamin D supplementation.</p><p></p><p class="bulletIndent1">Although calcium and vitamin D supplementation is necessary, it is generally not sufficient to prevent bone loss and fracture in patients taking high-dose glucocorticoids [<a href="#rid9">9-12</a>]. Pharmacologic therapy is often required. (See <a class="local">'Candidates for pharmacologic therapy'</a> below and <a class="local">'Bisphosphonates'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Active vitamin D metabolites</strong> – Vitamin D metabolites that are more active than vitamin D itself, such as <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> and <a class="drug drug_general" data-topicid="16467" href="/z/d/drug information/16467.html" rel="external">alfacalcidol</a>, have been evaluated for the prevention and treatment of glucocorticoid-induced bone loss [<a href="#rid13">13</a>]. Calcitriol (1,25-dihydroxyvitamin D, the most active metabolite of vitamin D) plus calcium protects against spine bone loss more than calcium alone in patients taking glucocorticoids [<a href="#rid10">10,14</a>]. A meta-analysis of five trials of active vitamin D metabolites in patients exposed to corticosteroids reported a beneficial effect of vitamin D metabolites on lumbar spine BMD [<a href="#rid13">13</a>]. There were insufficient data to address fracture prevention.</p><p></p><p class="bulletIndent1">Active vitamin D metabolites are less commonly used, however, because of the risks of hypercalcemia and hypercalciuria in patients whose urinary calcium excretion is already increased and because more effective therapies are available [<a href="#rid15">15</a>]. The superior efficacy of bisphosphonates compared with an active vitamin D metabolite for preventing glucocorticoid-induced bone loss has been demonstrated in several randomized trials [<a href="#rid16">16-21</a>]. Although not statistically significant, one trial showed that compared with <a class="drug drug_general" data-topicid="16467" href="/z/d/drug information/16467.html" rel="external">alfacalcidol</a>, fewer patients randomly assigned to <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> had new vertebral fractures (three versus eight patients) [<a href="#rid17">17</a>]. (See <a class="local">'Bisphosphonates'</a> below.)</p><p></p><p class="headingAnchor" id="H622797"><span class="h1">CANDIDATES FOR PHARMACOLOGIC THERAPY</span><span class="headingEndMark"> — </span>Our approach described below is largely in agreement with various guidelines, which collectively suggest pharmacologic therapy for patients based upon fracture risk. (See <a class="local">'Guidelines'</a> below.)</p><p class="headingAnchor" id="H1382752167"><span class="h2">Fracture risk assessment</span><span class="headingEndMark"> — </span>Patients with the highest risk for fracture are the ones most likely to benefit from drug therapy. Thus, selection of patients based upon fracture risk, as determined by a combination of bone mineral density (BMD) and clinical risk factors, is desirable. (See  <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis", section on 'Evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with established osteoporosis (history of fragility fracture or BMD T-score ≤-2.5) are at the highest risk for fracture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients without established osteoporosis, fracture risk can be assessed using a fracture risk calculator, such as the Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2034" target="_blank">FRAX</a>).</p><p></p><p class="bulletIndent1">FRAX estimates the 10-year probability of fracture for untreated patients between ages 40 and 90 years, using femoral neck BMD and clinical risk factors, including glucocorticoid exposure. FRAX does not account for glucocorticoid dose or duration, and therefore, FRAX risk estimates must be corrected according to the dose of glucocorticoid [<a href="#rid22">22</a>]. For patients taking <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> &gt;7.5 mg/day or equivalent, the risk estimate should be increased by 15 percent for major osteoporotic fracture and by 20 percent for hip fracture [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'</a>.)</p><p></p><p class="bulletIndent1">In North America, reasonable glucocorticoid-corrected thresholds to indicate high, moderate, and low risk of fracture are as follows [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High risk – A 10-year probability of hip or combined major osteoporotic fracture of ≥3 and 20 percent, respectively</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate risk – A 10-year probability of hip or combined major osteoporotic fracture between 1 to 3 percent and 10 to 19 percent, respectively</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low risk – A 10-year probability of hip or combined major osteoporotic fracture of ≤1 and &lt;10 percent, respectively</p><p></p><p>Some patients receiving glucocorticoids are at high risk, even if they fail to meet the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2034" target="_blank">FRAX</a> criteria for high risk. As an example, for patients with clinical risk factors for fracture, low lumbar spine BMD, but normal femoral neck BMD, FRAX is likely to underestimate fracture risk. This situation is especially likely in patients taking glucocorticoids, which are more likely to cause osteoporosis of the spine than of the hip. Thus, intervention guidelines with or without the use of FRAX provide only general clinical guidance. Treatment should remain individualized through shared decision-making between patient and clinician.</p><p>Fracture risk assessment, including the FRAX tool and its limitations, is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Clinical application of fracture risk assessment'</a> and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Limitations'</a>.)</p><p class="headingAnchor" id="H601849042"><span class="h2">Postmenopausal women and men aged ≥50 years</span><span class="headingEndMark"> — </span>Pharmacologic therapy is indicated for postmenopausal women and men ≥50 years with moderate to high risk of fracture. (See <a class="local">'Fracture risk assessment'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>For men ≥50 years and postmenopausal women (who are initiating or are chronically treated with any dose of glucocorticoids for any duration) who have osteoporosis (previous fragility fracture and/or a BMD T-score ≤-2.5) at initial assessment, we recommend pharmacologic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For high-risk men ≥50 years and postmenopausal women who are initiating or are chronically treated with any dose of glucocorticoids for any duration and have T-scores between -1.0 and -2.5, we suggest pharmacologic therapy. A reasonable threshold to indicate high risk in some settings is a glucocorticoid-corrected, FRAX-calculated, 10-year probability of hip or combined major osteoporotic fracture of ≥3 or 20 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For postmenopausal women and men ≥50 years with T-scores between -1.0 and -2.5 who have a glucocorticoid-corrected, FRAX-calculated absolute risk below these thresholds, we suggest pharmacologic therapy if they are taking ≥7.5 mg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or its equivalent for an anticipated duration of ≥3 months.</p><p></p><p>These recommendations are based upon randomized trial data showing that pharmacologic therapy improves BMD in patients taking glucocorticoids [<a href="#rid23">23,24</a>] and additional randomized trial data showing that pharmacologic therapy reduces fracture in men and postmenopausal women with established osteoporosis [<a href="#rid25">25</a>]. (See <a class="local">'Efficacy'</a> below and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a>.)</p><p class="headingAnchor" id="H622811"><span class="h2">Premenopausal women and younger men</span><span class="headingEndMark"> — </span>In the absence of definitive data, the decision to initiate pharmacologic therapy should be individualized in premenopausal women and younger men. The FRAX tool was not developed for use in men &lt;40 years or premenopausal women. In premenopausal women and younger men included in clinical trials for glucocorticoid-induced osteoporosis, fractures were generally infrequent in both treated and control groups [<a href="#rid12">12,26-28</a>]. Fracture risk in these patients taking glucocorticoids is not clearly defined and may differ from reported fracture risk in other glucocorticoid-treated populations. In addition, the presence or absence of hypogonadism may influence fracture risk and decisions about nonhormonal pharmacologic therapy.</p><p class="headingAnchor" id="H3256381130"><span class="h3">Hypogonadal patients</span><span class="headingEndMark"> — </span>Glucocorticoids may increase bone resorption by decreasing secretion of androgens and estrogens, mediated primarily by inhibition of gonadotropin secretion [<a href="#rid29">29</a>]. Therefore, it is logical to replace these hormones in women or men with confirmed hypogonadism, as long as there are no contraindications. (See  <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea"</a> and  <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premenopausal women</strong> – For premenopausal women of childbearing potential who are taking or initiating glucocorticoids and who are hypogonadal, we suggest treatment of hypogonadism. (See  <a class="medical medical_review" href="/z/d/html/110816.html" rel="external">"Functional hypothalamic amenorrhea: Evaluation and management", section on 'Estrogen replacement'</a>.)</p><p></p><p class="bulletIndent1">In a cross-sectional study of 119 perimenopausal women with asthma (65 receiving oral glucocorticoids), only those women who were not taking menopausal hormone therapy had lower mean BMD than healthy, aged-matched control women [<a href="#rid30">30</a>]. This observation plus the extensive literature supporting the value of menopausal hormone therapy in the prevention of postmenopausal osteoporosis makes it likely that appropriate treatment of hypogonadism can help reduce or reverse bone loss in premenopausal, hypogonadal women treated with glucocorticoids. (See  <a class="medical medical_review" href="/z/d/html/7428.html" rel="external">"Menopausal hormone therapy in the prevention and treatment of osteoporosis", section on 'Efficacy of estrogen therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Men</strong> – Bisphosphonates are first-line therapy for prevention and treatment of glucocorticoid-induced osteoporosis in men because they are known to reduce fracture risk. Men who develop symptomatic hypogonadism should also be treated with <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> for its benefits on muscle, energy, and libido, as well as on bone [<a href="#rid31">31,32</a>]. A number of testosterone preparations are available for the treatment of testosterone deficiency. (See  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Congenital hypogonadism'</a> and  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Choice of testosterone regimen'</a>.)</p><p></p><p class="headingAnchor" id="H927697335"><span class="h3">Eugonadal patients</span><span class="headingEndMark"> — </span>In the absence of definitive data, pharmacologic therapy should be individualized in eugonadal men and women. We generally treat such patients if they are at moderate to high risk for fracture. (See <a class="local">'Fracture risk assessment'</a> above.)</p><p>Potential short- and long-term risks, as well as potential effects on the fetus, should be considered as part of the decision to use bisphosphonates or <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> for the treatment of premenopausal osteoporosis. An effective plan for pregnancy prevention should be implemented. (See <a class="local">'Choice of therapy'</a> below and  <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">"Epidemiology and etiology of premenopausal osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For premenopausal women with normal ovarian function who have a fragility fracture while receiving glucocorticoids, we suggest pharmacologic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For similar women who do not have a fragility fracture but have accelerated bone loss (≥4 percent/year) or Z-score &lt;-3 while receiving glucocorticoids (7.5 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> equivalent for ≥3 months), we also suggest pharmacologic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For men &lt;50 years of age who have a fragility fracture while receiving glucocorticoids, we suggest pharmacologic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For similar men who do not have a fragility fracture but have accelerated bone loss (≥4 percent/year) or Z-score &lt;-3 while receiving glucocorticoids (7.5 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> equivalent for ≥3 months), we also suggest pharmacologic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also suggest pharmacologic therapy for men &lt;50 years and premenopausal women taking <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> &gt;30 mg/day for &gt;1 month.</p><p></p><p class="headingAnchor" id="H2578621"><span class="h1">CHOICE OF THERAPY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Men and postmenopausal women</strong> – For pharmacologic therapy for men and postmenopausal women, we favor bisphosphonates as first-line therapy. We prefer <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a> because of clinical trial data demonstrating efficacy in men and women with glucocorticoid-induced osteoporosis. For such patients who cannot tolerate oral bisphosphonates or who have difficulty with the dosing requirements or adherence, intravenous (IV) <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> is an acceptable alternative. (See <a class="local">'Bisphosphonates'</a> below and  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Oral regimen'</a> and  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'IV regimen'</a>.)</p><p></p><p class="bulletIndent1">We typically reserve parathyroid hormone (<a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>, PTH) for patients with severe osteoporosis (T-score of -3.5 or below even in the absence of fractures or a T-score of -2.5 or below plus a fragility fracture). In addition, teriparatide is an option for patients who are unable to tolerate any of the available bisphosphonates or who continue to fracture after one year of bisphosphonate therapy. (See <a class="local">'Parathyroid hormone'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> is also an alternate therapeutic option for those at high risk for fracture. However, due to the increased risk of vertebral fracture after discontinuation of denosumab, the need for a careful "exit strategy" if denosumab is stopped should be discussed with patients prior to its initiation. (See <a class="local">'Other pharmacologic therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premenopausal women</strong> – For premenopausal women with fractures or accelerated bone loss and with normal ovarian function, bisphosphonates are generally the drugs of choice (see <a class="local">'Bisphosphonates'</a> below). <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a> is an alternative option for such women, as long as epiphyses are fully fused (see <a class="local">'Parathyroid hormone'</a> below). Potential short- and long-term risks, as well as potential effects on the fetus, should be considered as part of the decision to use bisphosphonates or teriparatide for the treatment of premenopausal osteoporosis. (See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis", section on 'Antiresorptive therapy with bisphosphonates'</a> and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis", section on 'Anabolic therapy with teriparatide'</a>.)</p><p></p><p class="bulletIndent1">We do not typically prescribe <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for the prevention or treatment of glucocorticoid-induced osteoporosis in premenopausal women. (See <a class="local">'Other pharmacologic therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H4160099119"><span class="h1">EFFICACY</span></p><p class="headingAnchor" id="H5"><span class="h2">Bisphosphonates</span><span class="headingEndMark"> — </span>There are substantial data supporting the use of antiresorptive agents, such as the bisphosphonates, for the prevention and treatment of glucocorticoid-induced bone loss. In a meta-analysis of 27 randomized trials evaluating bisphosphonates (alone or in combination with calcium and vitamin D) versus calcium and vitamin D (alone or with placebo) for the prevention and treatment of glucocorticoid-induced osteoporosis, there was significant improvement in lumbar spine (absolute difference 3.5 percent) and femoral neck bone mineral density (BMD) (absolute difference 2.1 percent) in the bisphosphonate group [<a href="#rid24">24</a>]. There was a reduction in the risk of new vertebral fracture with bisphosphonates (44 versus 77 per 1000 persons in the bisphosphonate and no treatment groups, respectively, risk ratio [RR] 0.57, 95% CI 0.35-0.91). The reduction in risk of nonvertebral fracture did not reach statistical significance (42 versus 55 per 1000 persons, RR 0.79, 95% CI 0.47-1.33).</p><p>Few premenopausal women were included in the large clinical trials [<a href="#rid24">24</a>], and fractures were generally infrequent in both treated and control groups [<a href="#rid12">12,26,27</a>]. Two small clinical trials that included premenopausal women with corticosteroid-treated connective tissue diseases (CTD) used the less potent first-generation bisphosphonate, <a class="drug drug_general" data-topicid="8426" href="/z/d/drug information/8426.html" rel="external">etidronate</a>, as the antiresorptive agent and found successful maintenance of BMD in the women taking the drug [<a href="#rid33">33,34</a>]. </p><p>The therapeutic efficacy of bisphosphonates in patients with glucocorticoid-induced osteoporosis has been thought to be related to their ability to promote osteoclast apoptosis (programmed cell death) [<a href="#rid35">35</a>]. However, glucocorticoids may negate the pro-apoptotic effect of bisphosphonates, suggesting that these drugs may prevent glucocorticoid-induced bone loss by prolonging the lifespan of osteoblasts [<a href="#rid35">35,36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alendronate</strong><strong> </strong>– The efficacy of <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> in patients receiving glucocorticoid therapy was demonstrated in a study of 477 patients age 17 to 83 years who were randomly assigned to receive one of two doses of alendronate or placebo [<a href="#rid12">12</a>]. The mean BMD of the lumbar spine increased by 2.1 and 2.9 percent over 48 weeks in the patients receiving 5 and 10 mg of alendronate daily, respectively, while decreasing 0.4 percent in the placebo group. Femoral neck, trochanter, and total body BMD also increased significantly in the alendronate groups  (<a class="graphic graphic_figure graphicRef52447" href="/z/d/graphic/52447.html" rel="external">figure 1</a>). Those receiving alendronate had fewer new vertebral fractures compared with placebo (2.3 versus 3.7 percent), although fracture was not a primary outcome. These benefits were maintained for two years [<a href="#rid37">37</a>]. Once-weekly alendronate (70 mg) similarly improves BMD [<a href="#rid38">38</a>], and in a retrospective cohort study, alendronate was associated with a significantly lower risk of hip fracture in older patients taking oral <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risedronate</strong> – <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">Risedronate</a> is also effective for the prevention and treatment of osteoporosis, including glucocorticoid-induced osteoporosis [<a href="#rid11">11,40,41</a>]. In a one-year study of risedronate versus placebo in 290 patients receiving glucocorticoids (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> ≥7.5 mg/day for six or more months), lumbar spine and femoral neck BMD increased by 2.7 and 1.8 percent, respectively, in the risedronate group, as compared with no change in the placebo group [<a href="#rid40">40</a>]. The relative risk of vertebral fracture (a secondary outcome) was reduced by 70 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zoledronic acid</strong> – The efficacy of <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> for the prevention and treatment of glucocorticoid-induced osteoporosis was demonstrated in a one-year, randomized trial of IV zoledronic acid (5 mg once) or daily oral <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a> (5 mg) in 288 patients who recently started glucocorticoids (prevention group) and 545 patients who had been taking them for more than three months (treatment group) [<a href="#rid42">42</a>]. In an analysis of patients who received the study drug and had baseline and follow-up BMD measurements, zoledronic acid and risedronate increased mean BMD of the lumbar spine in both the prevention (2.6 and 0.6 percent, respectively) and treatment (4.1 and 2.7 percent, respectively) groups. The study was not designed to evaluate fractures, which occurred in three and five subjects in the risedronate and zoledronic acid groups, respectively.</p><p></p><p class="bulletIndent1">During the first three days, the occurrence of adverse events (predominantly arthralgias, fever, and flu-like symptoms) was greater in the <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> group. (See  <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Risks specific to intravenous bisphosphonates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other bisphosphonates </strong>– Oral and IV <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a> have been shown to prevent glucocorticoid-induced bone loss [<a href="#rid9">9,43-45</a>]. However, pamidronate is rarely used now that <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> is available.</p><p></p><p class="bulletIndent1">There are few data evaluating the efficacy of oral <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a> for the prevention and treatment of glucocorticoid-induced osteoporosis. However, IV ibandronate appears to preserve BMD. In an open-label, randomized trial of ibandronate (2 mg IV every three months for two years) versus <a class="drug drug_general" data-topicid="16467" href="/z/d/drug information/16467.html" rel="external">alfacalcidol</a> (1 mcg daily) in 104 patients with established glucocorticoid-induced osteoporosis, IV ibandronate resulted in superior improvements in spine, femoral neck, and calcaneal BMD compared with alfacalcidol (between-group differences of 9.7, 3.4, and 7.9 percent, respectively) [<a href="#rid18">18</a>]. These improvements were sustained in a third year of treatment, and there were fewer vertebral fractures (a secondary outcome) in the ibandronate group compared with the alfacalcidol group (8.6 versus 22.8 percent) [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Parathyroid hormone</span><span class="headingEndMark"> — </span>Parathyroid hormone (<a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>, PTH) is generally not used as a first-line drug for treatment or prevention of glucocorticoid-induced osteoporosis, because of its cost, subcutaneous route of administration, and the availability of other agents. However, PTH is an option for the treatment of glucocorticoid-induced osteoporosis in men or postmenopausal women who:</p><p class="bulletIndent1"><span class="glyph">●</span>Have severe osteoporosis (T-score of -3.5 or below even in the absence of fractures; T-score of -2.5 or below plus a fragility fracture) before initiating glucocorticoids</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Have osteoporosis (T-score below -2.5) who are unable to tolerate oral or IV bisphosphonates, or who have relative contraindications to bisphosphonates (achalasia, scleroderma esophagus, esophageal strictures)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fail other osteoporosis therapies (fracture with loss of BMD in spite of compliance with therapy)</p><p></p><p><a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a> is also an option for premenopausal women, as long as epiphyses are fully fused, who have fragility fractures or accelerated bone loss (≥4 percent/year) while receiving glucocorticoids (7.5 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> equivalent for ≥3 months) and who do not need estrogen replacement therapy because they have normal menstrual function.</p><p>Due to the lack of proven efficacy beyond two years, a single course of <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> in most patients is limited to two years duration. Treatment with an antiresorptive agent (eg, bisphosphonates) after PTH preserves the gains in BMD achieved with PTH. Thus, for patients who receive teriparatide as initial treatment and who remain at high risk for fracture after discontinuation, a bisphosphonate should be started after PTH is discontinued. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis"</a>.)</p><p>PTH stimulates bone formation as well as resorption, and intermittent administration stimulates formation more than resorption. Because the predominant effect of glucocorticoids on the skeleton is to reduce bone formation and bisphosphonates (antiresorptive agents) do not address this mechanism of bone loss, treatment with PTH is theoretically a more appealing approach [<a href="#rid46">46</a>].</p><p>In randomized trials, PTH is effective in improving BMD in patients treated with glucocorticoids [<a href="#rid23">23,47-49</a>]. As an example, in an 18-month, randomized trial of <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> (10 mg orally daily) versus PTH (1-34) (<a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>, 20 mcg subcutaneously daily) in 428 men and women who had taken glucocorticoids for ≥3 months (≥5 mg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> equivalent daily), both treatments significantly increased BMD. However, teriparatide was associated with a greater increase in lumbar spine (8.2 versus 3.9 percent), total hip (3.8 versus 2.4 percent), and femoral neck (4.4 versus 2.8 percent) BMD [<a href="#rid23">23</a>]. There was no difference in the incidence of nonvertebral fractures, a secondary outcome (5.6 versus 3.7 percent), but there were fewer new radiographic vertebral fractures (1 versus 10) in subjects randomly assigned to teriparatide compared with alendronate. Thirty percent of subjects in each treatment group discontinued the study prior to completion. There was more nausea and insomnia in the teriparatide group and more rashes in the alendronate group.</p><p>The trial was designed to have an 18-month continuation phase, with prespecified secondary outcomes that included BMD, fractures, and adverse events at 36 months [<a href="#rid47">47</a>]. After 36 months (n = 241 subjects), increases in BMD from baseline remained significantly greater in the <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> group (11 versus 5.3, 5.2 versus 2.7, and 6.3 versus 3.4 percent for lumbar spine, total hip, and femoral neck, respectively). New vertebral fractures occurred significantly less often in patients receiving teriparatide (3 versus 13 in the <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> group). The majority of vertebral fractures occurred in the first 18 months. There was no difference in the incidence of nonvertebral fractures.</p><p>Premenopausal women with glucocorticoid-induced osteoporosis also benefit from treatment with <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> [<a href="#rid23">23</a>]. In a secondary analysis of the randomized trial of teriparatide versus <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> in patients with glucocorticoid-induced osteoporosis, the increase in lumbar spine BMD was significantly greater in the teriparatide group for both premenopausal (7.0 versus 0.7 percent) and postmenopausal (7.8 versus 3.7 percent) women [<a href="#rid26">26</a>]. In premenopausal women, fractures were infrequent in both treatment groups.</p><p><a class="drug drug_general" data-topicid="112992" href="/z/d/drug information/112992.html" rel="external">Abaloparatide</a>, a synthetic analog of parathyroid hormone-related protein (PTHrP) has not been evaluated as a treatment for glucocorticoid-induced osteoporosis. Its use for osteoporosis of other etiologies is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis"</a>.) </p><p class="headingAnchor" id="H16"><span class="h2">Other pharmacologic therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Denosumab</strong> – We do not typically prescribe <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for the prevention or treatment of glucocorticoid-induced osteoporosis. Denosumab may be beneficial in some patients with glucocorticoid-induced osteoporosis [<a href="#rid50">50-52</a>]. However, emerging data have raised concern about increased risk of vertebral fracture after discontinuation of denosumab, and the need for a careful "exit strategy" if denosumab is stopped should be discussed with patients prior to its initiation. If denosumab is discontinued, administering an alternative therapy (typically a bisphosphonate) to prevent rapid bone loss and vertebral fracture is strongly advised. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Increased vertebral fractures'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> is a monoclonal antibody to an osteoclast differentiating factor. It inhibits osteoclast formation, decreases bone resorption, increases BMD, and reduces the risk of fracture. It has been used in postmenopausal women and in men undergoing androgen deprivation therapy for prostate cancer. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Denosumab'</a>.)</p><p></p><p class="bulletIndent1">In a noninferiority trial evaluating <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> versus <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a> in 505 patients receiving glucocorticoids for ≥3 months and 290 patients who were initiating glucocorticoids (&lt;3 months), the increase in lumbar spine BMD was greater with denosumab (4.4 versus 2.3 percent for glucocorticoid continuing and 3.8 versus 0.8 percent for glucocorticoid initiating) [<a href="#rid50">50,51</a>]. There was no difference in adverse events, including the incidence of fracture (osteoporosis-related fractures, 7 and 6 percent, respectively; new and worsening vertebral fractures in postmenopausal women, 5 percent in each group). Denosumab also increased BMD in a prospective, observational study of 36 patients treated with glucocorticoids for pulmonary disease [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Romosozumab</strong> – There are no data about the use of <a class="drug drug_general" data-topicid="120976" href="/z/d/drug information/120976.html" rel="external">romosozumab</a>, an anabolic based on an antibody to sclerostin, for the prevention or treatment of glucocorticoid osteoporosis. Its use for osteoporosis is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Romosozumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcitonin</strong> – We do not use <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">calcitonin</a> for the treatment or prevention of glucocorticoid-induced osteoporosis, because more effective drugs (eg, bisphosphonates, <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>) are available for the prevention of bone loss and reduction of fracture risk. Another concern is that the long-term use of calcitonin for osteoporosis has been associated with an increase in cancer rates. (See  <a class="medical medical_review" href="/z/d/html/2025.html" rel="external">"Calcitonin in the prevention and treatment of osteoporosis", section on 'Concerns about the use of calcitonin'</a>.)</p><p></p><p class="headingAnchor" id="H2707788"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>There are several published guidelines for monitoring the response to osteoporosis therapy. Although all recommend follow-up bone mineral density (BMD) testing, there is no consensus on the optimal frequency of monitoring and the preferred site to monitor. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Monitoring response to initial pharmacotherapy'</a>.)</p><p>We typically measure BMD (dual-energy x-ray absorptiometry [DXA]) of the lumbar spine and hip at the initiation of glucocorticoid therapy and after one year.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>BMD stable or improved</strong> – If BMD is stable or improved, we measure it less frequently (every two to three years) thereafter. If glucocorticoids are discontinued and BMD is stable, measurement at five-year intervals may be sufficient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BMD decreased</strong> – The finding of a BMD decrease greater than the least significant change or a new fracture in a treated patient should trigger additional evaluation for contributing factors, which may include poor adherence to therapy, inadequate gastrointestinal absorption, inadequate intake of calcium and vitamin D, or the development of a disease or disorder with adverse skeletal effects. Switching from oral bisphosphonates to intravenous (IV) <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> may be effective in patients with poor absorption or poor compliance with the oral regimen. Alternative options for patients who fail oral bisphosphonate therapy are similar to those for patients with osteoporosis in general. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'BMD decreased or fracture during therapy'</a>.)</p><p></p><p>There may be a significant increase in bone density after discontinuation of exogenous glucocorticoid therapy or reversal of endogenous Cushing syndrome [<a href="#rid54">54,55</a>]. One study, as an example, examined spine BMD after successful treatment for Cushing disease in 20 patients, all of whom had marked osteoporosis of lumbar spine and femoral neck [<a href="#rid54">54</a>]. There was no change in BMD for six months, the time required for gradual reversal of increased osteoclastic activity, after which BMD increased. However, patients who have had a fracture may have permanent deformity.</p><p class="headingAnchor" id="H21"><span class="h1">GUIDELINES</span><span class="headingEndMark"> — </span>The American College of Rheumatology (ACR) guidelines recommend intervention based upon risk of fracture (high, medium, low), guided in part by the Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2034" target="_blank">FRAX</a>) [<a href="#rid3">3,56</a>]. FRAX is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a>.)</p><p>For adults ≥40 years, low, medium, and high risk are defined as follows [<a href="#rid3">3,56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk – 10-year risk of hip or a major osteoporotic fracture of ≤1 and &lt;10 percent, respectively</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medium risk – 10-year risk of hip or a major osteoporotic fracture &gt;1 to &lt;3 percent and 10 to 19 percent, respectively</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk – History of a fragility fracture, a lumbar spine or hip T-score below -2.5, or 10-year risk of hip or a major osteoporotic fracture ≥3 and 20 percent, respectively</p><p></p><p>For adults &lt;40 years, low, medium, and high risk are defined as follows [<a href="#rid3">3,56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk – No medium- or high-risk factors other than glucocorticoid treatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medium risk – Hip or spine Z-score &lt;-3, or rapid bone loss (≥10 percent over one year) and continuing glucocorticoid treatment at ≥7.5 mg/day for ≥6 months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk – History of a fragility fracture</p><p></p><p>In addition to lifestyle modification and calcium and vitamin D supplementation, the ACR guidelines recommend oral bisphosphonates for adults at medium or high risk of major fracture. If oral bisphosphonates contraindicated or not tolerated, options include intravenous (IV) bisphosphonates, <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>, <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>, and <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a>. For premenopausal women of childbearing potential, confirm there are no plans for pregnancy during the period of osteoporosis treatment and that effective contraception is utilized.</p><p>The patient should be followed yearly to determine if bone loss continues. An exercise program should also be initiated, although this may be limited by restrictions from the underlying illness. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Exercise'</a>.)</p><p>Other published guidelines largely agree with the recommendations above, except for some minor differences:</p><p class="bulletIndent1"><span class="glyph">●</span>The National Osteoporosis Guideline Group in the United Kingdom recommends using <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2034" target="_blank">FRAX</a> (adjusted for glucocorticoid dose) to determine assessment thresholds (fracture probabilities for bone mineral density [BMD] testing) and intervention thresholds (fracture probabilities for therapeutic intervention) [<a href="#rid57">57,58</a>]. In general, antiresorptive therapy should be initiated at the time of starting glucocorticoids in patients at highest risk for fracture (eg, ≥70 years of age, history of prior fragility fracture, or taking large doses of glucocorticoids [ie, ≥7.5 mg <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>/day]). Good nutrition, adequate dietary calcium intake, and a bisphosphonate are recommended as therapy. <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">Alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a> are the preferred bisphosphonates because of efficacy and low cost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The International Osteoporosis Foundation and the European Calcified Tissue Society recommend osteoporosis therapy in postmenopausal women and men who are ≥70 years, have a previous fragility fracture, or a dose of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> ≥7.5 mg daily (or its equivalent) for ≥3 months [<a href="#rid59">59,60</a>]. For those at highest risk, bone protective therapy should be started at the onset of glucocorticoid therapy. For patients who do not meet these criteria, fracture risk should be assessed using <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2034" target="_blank">FRAX</a> with intervention thresholds based upon country-specific population fracture risks and health economic assessments and corrected for glucocorticoid exposure. For premenopausal women and men &lt;50 years of age who are taking glucocorticoids for ≥3 months, osteoporosis therapy is considered for those with a history of a fragility fracture. For all others, treatment decisions are individualized based upon patient characteristics and clinical judgement.</p><p></p><p class="headingAnchor" id="H2853055625"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15482.html" rel="external">"Patient education: Osteoporosis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15536.html" rel="external">"Patient education: Calcium and vitamin D for bone health (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2160.html" rel="external">"Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2169.html" rel="external">"Patient education: Calcium and vitamin D for bone health (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – In an attempt to minimize bone loss, glucocorticoid dose and the duration of therapy should be as low and as short as possible, respectively, because even replacement doses can cause bone loss. Patients should be encouraged to do weightbearing exercises for protection against both bone loss and muscle atrophy. Patients should avoid smoking and excess alcohol and take measures to prevent falls. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium and vitamin D</strong> – For all patients receiving any dose of chronic glucocorticoid therapy or initiating glucocorticoids with an anticipated duration of ≥3 months, we suggest calcium and vitamin D supplementation (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Most individuals require 1200 mg of elemental calcium daily, total diet plus supplement, and 800 international units of vitamin D daily. (See <a class="local">'Calcium and vitamin D'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for pharmacotherapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postmenopausal women and men aged ≥50 years</strong> – For men aged ≥50 years and postmenopausal women with established osteoporosis (T-score ≤-2.5 or fragility fracture) who are receiving or are about to initiate glucocorticoids (any dose for any duration), we recommend pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Postmenopausal women and men aged ≥50 years'</a> above.)</p><p></p><p class="bulletIndent2">For high-risk men aged ≥50 years and postmenopausal women who are initiating or are treated with any dose of glucocorticoids for any duration and who have T-scores between -1.0 and -2.5, we suggest pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). A reasonable threshold to indicate high risk in some settings is a glucocorticoid-corrected, Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2034" target="_blank">FRAX</a>)-calculated, 10-year probability of hip or combined major osteoporotic fracture of ≥3 or 20 percent, respectively. For postmenopausal women and men aged ≥50 years who have a FRAX-calculated absolute risk below these thresholds, we suggest pharmacologic therapy if they are taking ≥7.5 mg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or its equivalent for an anticipated duration of ≥3 months (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Postmenopausal women and men aged ≥50 years'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Premenopausal women and younger men</strong> – In the absence of definitive data, the decision to initiate pharmacologic therapy should be individualized in premenopausal women and younger men through shared decision-making between patient and clinician. (See <a class="local">'Premenopausal women and younger men'</a> above and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis", section on 'Secondary cause identified'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hypogonadal patients</strong> – Glucocorticoids may increase bone resorption by decreasing secretion of androgens and estrogens, mediated primarily by inhibition of gonadotropin secretion. Therefore, premenopausal women or men with confirmed hypogonadism should receive appropriate treatment (provided no contraindications are present). (See <a class="local">'Hypogonadal patients'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Eugonadal patients</strong> – For premenopausal women with normal ovarian function who have a fragility fracture while receiving glucocorticoids, we suggest pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For similar women who do not have a fragility fracture but have accelerated bone loss (≥4 percent/year) or Z-score &lt;-3 while receiving glucocorticoids (7.5 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> equivalent for ≥3 months), we also suggest pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Premenopausal women and younger men'</a> above.)</p><p></p><p class="bulletIndent3">For men &lt;50 years of age who have a fragility fracture while receiving glucocorticoids,<strong> </strong>we suggest pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For similar men who do not have a fragility fracture but have accelerated bone loss (≥4 percent/year) or Z-score &lt;-3, while receiving glucocorticoids (7.5 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> equivalent for ≥3 months), we also suggest pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Premenopausal women and younger men'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Men and postmenopausal women</strong> – For men and postmenopausal women who are candidates for pharmacologic therapy, we suggest bisphosphonates over other available agents as first-line therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We prefer weekly oral <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a> over other oral bisphosphonates because of clinical trial data demonstrating efficacy in women and men with glucocorticoid-induced osteoporosis. Intravenous (IV) <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> is an option for patients unable to tolerate oral bisphosphonates or who have difficulty with the dosing requirements or adherence to oral therapy. (See <a class="local">'Choice of therapy'</a> above and <a class="local">'Bisphosphonates'</a> above.)</p><p></p><p class="bulletIndent2">Parathyroid hormone (<a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>, PTH) is generally not used as a first-line drug for treatment or prevention of glucocorticoid-induced osteoporosis, because of its cost, subcutaneous route of administration, and the availability of other agents. However, for the prevention or treatment of glucocorticoid-induced osteoporosis in men or postmenopausal women with osteoporosis (T-score below -2.5) who are unable to tolerate any of the available bisphosphonates, we suggest PTH over other available therapies (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Other candidates for PTH include patients with severe osteoporosis (T-score of -3.5 or below even in the absence of fractures or a T-score of -2.5 or below plus a fragility fracture) and patients who fail other osteoporosis therapies (fracture with loss of bone mineral density [BMD] in spite of compliance with therapy). <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> is also an alternate therapeutic option for those at high risk for fracture. However, due to the increased risk of vertebral fracture after discontinuation of denosumab, the need for a careful "exit strategy" if denosumab is stopped should be discussed with patients prior to its initiation. (See <a class="local">'Choice of therapy'</a> above and <a class="local">'Parathyroid hormone'</a> above and <a class="local">'Other pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Premenopausal women</strong> – For premenopausal women of childbearing potential who are candidates for pharmacologic therapy, we suggest bisphosphonates as first-line therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a> is an alternative option for such women, as long as epiphyses are fully fused. (See <a class="local">'Bisphosphonates'</a> above and <a class="local">'Parathyroid hormone'</a> above and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis", section on 'Choice of therapy'</a>.)</p><p></p><p class="bulletIndent2">For premenopausal women of childbearing potential, confirm there are no plans for pregnancy during the period of osteoporosis treatment and that an effective plan for pregnancy prevention is implemented. It is important to consider the potential for harm to the fetus in women who become pregnant and are currently receiving <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> or who are currently receiving or were recently treated with bisphosphonates. (See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis", section on 'Pharmacologic therapy for selected women'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – We typically measure BMD at the initiation of glucocorticoid therapy and after one year. If BMD is stable or improved, we measure BMD less frequently (every two to three years) thereafter. (See <a class="local">'Monitoring'</a> above and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Monitoring response to initial pharmacotherapy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777.</a></li><li><a class="nounderline abstract_t">Heffernan MP, Saag KG, Robinson JK, Callen JP. Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA 2006; 295:1300.</a></li><li><a class="nounderline abstract_t">Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2017; 69:1521.</a></li><li><a class="nounderline abstract_t">Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 2019; 30:1145.</a></li><li><a class="nounderline abstract_t">Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994; 120:207.</a></li><li><a class="nounderline abstract_t">Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18:1319.</a></li><li><a class="nounderline abstract_t">Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; :CD000952.</a></li><li><a class="nounderline abstract_t">Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125:961.</a></li><li><a class="nounderline abstract_t">Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001; 16:104.</a></li><li><a class="nounderline abstract_t">Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328:1747.</a></li><li><a class="nounderline abstract_t">Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42:2309.</a></li><li><a class="nounderline abstract_t">Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292.</a></li><li><a class="nounderline abstract_t">Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15:301.</a></li><li><a class="nounderline abstract_t">Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.</a></li><li><a class="nounderline abstract_t">Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32:151.</a></li><li><a class="nounderline abstract_t">Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18:919.</a></li><li><a class="nounderline abstract_t">de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006; 355:675.</a></li><li><a class="nounderline abstract_t">Ringe JD, Dorst A, Faber H, et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford) 2003; 42:743.</a></li><li><a class="nounderline abstract_t">Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14:801.</a></li><li><a class="nounderline abstract_t">Kikuchi Y, Imakiire T, Yamada M, et al. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant 2007; 22:1593.</a></li><li><a class="nounderline abstract_t">Fujii N, Hamano T, Mikami S, et al. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 2007; 22:1601.</a></li><li><a class="nounderline abstract_t">Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011; 22:809.</a></li><li><a class="nounderline abstract_t">Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028.</a></li><li><a class="nounderline abstract_t">Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 2016; 10:CD001347.</a></li><li><a class="nounderline abstract_t">MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148:197.</a></li><li><a class="nounderline abstract_t">Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20:2095.</a></li><li><a class="nounderline abstract_t">Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337:382.</a></li><li><a class="nounderline abstract_t">Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67:277.</a></li><li><a class="nounderline abstract_t">MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104:648.</a></li><li><a class="nounderline abstract_t">Laatikainen AK, Kröger HP, Tukiainen HO, et al. Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study. Am J Respir Crit Care Med 1999; 159:1179.</a></li><li><a class="nounderline abstract_t">Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156:1173.</a></li><li><a class="nounderline abstract_t">Crawford BA, Liu PY, Kean MT, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88:3167.</a></li><li><a class="nounderline abstract_t">Nakayamada S, Okada Y, Saito K, Tanaka Y. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 2004; 31:163.</a></li><li><a class="nounderline abstract_t">Sato S, Ohosone Y, Suwa A, et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. J Rheumatol 2003; 30:2673.</a></li><li><a class="nounderline abstract_t">Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104:1363.</a></li><li><a class="nounderline abstract_t">Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109:1041.</a></li><li><a class="nounderline abstract_t">Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44:202.</a></li><li><a class="nounderline abstract_t">Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009; 36:1705.</a></li><li><a class="nounderline abstract_t">Axelsson KF, Nilsson AG, Wedel H, et al. Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. JAMA 2017; 318:146.</a></li><li><a class="nounderline abstract_t">Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15:1006.</a></li><li><a class="nounderline abstract_t">Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000; 11:331.</a></li><li><a class="nounderline abstract_t">Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373:1253.</a></li><li><a class="nounderline abstract_t">Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988; 1:143.</a></li><li><a class="nounderline abstract_t">Reid IR, Heap SW, King AR, Ibbertson HK. Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet 1988; 2:1144.</a></li><li><a class="nounderline abstract_t">Gallacher SJ, Fenner JA, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992; 47:932.</a></li><li><a class="nounderline abstract_t">Carpinteri R, Porcelli T, Mejia C, et al. Glucocorticoid-induced osteoporosis and parathyroid hormone. J Endocrinol Invest 2010; 33:16.</a></li><li><a class="nounderline abstract_t">Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60:3346.</a></li><li><a class="nounderline abstract_t">Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102:1627.</a></li><li><a class="nounderline abstract_t">Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013; 28:1355.</a></li><li><a class="nounderline abstract_t">Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 2018; 6:445.</a></li><li><a class="nounderline abstract_t">Saag KG, Pannacciulli N, Geusens P, et al. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis Rheumatol 2019; 71:1174.</a></li><li><a class="nounderline abstract_t">Mok CC, Ho LY, Leung SMT, et al. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial. Bone 2021; 146:115902.</a></li><li><a class="nounderline abstract_t">Ishiguro S, Ito K, Nakagawa S, et al. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos 2017; 12:44.</a></li><li><a class="nounderline abstract_t">Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995; 80:2859.</a></li><li><a class="nounderline abstract_t">Pocock NA, Eisman JA, Dunstan CR, et al. Recovery from steroid-induced osteoporosis. Ann Intern Med 1987; 107:319.</a></li><li class="breakAll">https://www.rheumatology.org/Portals/0/Files/Guideline-for-the-Prevention-and-Treatment-of-GIOP.pdf (Accessed on June 29, 2017).</li><li class="breakAll">https://www.sheffield.ac.uk/NOGG/NOGG_Executive_Summary.pdf (Accessed on July 11, 2017).</li><li><a class="nounderline abstract_t">Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017; 12:43.</a></li><li><a class="nounderline abstract_t">Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23:2257.</a></li><li class="breakAll">https://www.iofbonehealth.org/iof-ects-glucocorticoid-induced-osteoporosis-guidelines-working-group (Accessed on July 11, 2017).</li></ol></div><div id="topicVersionRevision">Topic 2034 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12378366" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16541489" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of osteoporosis associated with chronic glucocorticoid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28585373" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30805679" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Glucocorticoid-induced osteoporosis: 2019 concise clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8273983" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17566815" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Glucocorticoid-induced osteoporosis: pathophysiology and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796394" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Calcium and vitamin D for corticosteroid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8967706" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11149473" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7684512" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555025" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9682041" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14740153" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2407167" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Glucocorticoid-induced osteoporosis: pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6298567" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12733733" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914703" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12730532" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14610641" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17041001" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17124283" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21229233" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Guidance for the adjustment of FRAX according to the dose of glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18003959" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Teriparatide or alendronate in glucocorticoid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27706804" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bisphosphonates for steroid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18087050" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19350340" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241127" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11000340" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3083749" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Reduction of serum testosterone levels during chronic glucocorticoid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194163" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639011" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Testosterone therapy in glucocorticoid-treated men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843161" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14705236" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14719212" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10562298" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11956241" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11212161" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487264" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28697254" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841169" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928223" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19362675" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2892989" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2903360" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1465751" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20938221" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Glucocorticoid-induced osteoporosis and parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19877063" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788977" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23322362" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29631782" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30816640" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33631355" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28425086" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7559865" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3619221" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Recovery from steroid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3619221" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recovery from steroid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3619221" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Recovery from steroid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28425085" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : UK clinical guideline for the prevention and treatment of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22434203" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
